Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.74 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.56 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.56 |
| ▸ | TUBB | P07437 | 4/20 | 0.56 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.56 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.56 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.56 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.56 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.56 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.56 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.56 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.56 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.56 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.56 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.56 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17536647 | 0.92 | CYP19A1 (0.74) | CYP19A1TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL31275137 | 0.92 | CYP19A1 (0.74) | CYP19A1TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL15457886 | 0.85 | CYP19A1 (0.89) | CYP19A1TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL29386339 | 0.85 | CYP19A1 (1.00) | CYP19A1TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL10328452 | 0.85 | CYP19A1 (1.00) | CYP19A1TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL17536651 | 0.84 | CYP19A1 (0.62) | CYP19A1TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL14071710 | 0.84 | CYP19A1 (0.82) | CYP19A1TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL27183069 | 0.83 | CYP19A1 (0.72) | CYP19A1TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL3674958 | 0.82 | CYP19A1 (0.80) | CYP19A1TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL31511906 | 0.82 | CYP19A1 (0.80) | CYP19A1TUBB1TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994460-B1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | UNIV INDIANA RES & TECH CORP (US) | 2024-12-04 | — | — | EP | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | CYP19A1 260/4885TUBB1 393/4885TUBB4A 466/4885 |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | CYP19A1 260/4885TUBB1 393/4885TUBB4A 466/4885 |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | CYP19A1 260/4885TUBB1 393/4885TUBB4A 466/4885 |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | CYP19A1 260/4885TUBB1 393/4885TUBB4A 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.